Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-05-22
2007-05-22
Desai, Rita (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C546S116000
Reexamination Certificate
active
10919068
ABSTRACT:
A compound has the formulain racemic form, enantiomerically enriched form or enantiomerically pure form. R6is preferably —Si(R8R9R10) or —(R7)Si(R8R9R10), wherein R7is an alkylene group, an alkenylene group, or an alkynylene group; and R8, R9and R10are independently a C1-10alkyl group, a C2-10alkenyl group, a C2-10alkynyl group, an aryl group or a —(CH2)NR11group, wherein N is an integer within the range of 1 through 10 and R11is a hydroxy group, alkoxy group, an amino group, an alkylamino group, a dialkylamino group, a halogen atom, a cyano group, —SRcor a nitro group. R1–R4can be broadly substituted. R5is preferably a C1-10alkyl group, an alkenyl group, an alkynyl group, or a benzyl group. R13is preferably H, F or —CH3. R16is R16is —C(O)Rfor H. The E-ring (the lactone ring) may be opened. A method of synthesis of compound (1) and intermediates in the synthesis thereof are provided.
REFERENCES:
patent: 5468859 (1995-11-01), Fortunak
patent: 5700939 (1997-12-01), Fortunak
patent: 5744605 (1998-04-01), Curran
patent: 5910491 (1999-06-01), Hausheer
patent: 5935967 (1999-08-01), Hausheer
patent: 5981542 (1999-11-01), Bigg
patent: 6057303 (2000-05-01), Haridas
patent: 6136978 (2000-10-01), Curran
patent: 6150343 (2000-11-01), Curran
patent: WO 97/00876 (1997-01-01), None
patent: WO9700876 (1997-01-01), None
patent: WO 98/07727 (1998-02-01), None
patent: WO 98/28305 (1998-07-01), None
patent: WO9828304 (1998-07-01), None
patent: WO 98/35940 (1998-08-01), None
patent: WO 99/11646 (1999-03-01), None
patent: WO 00/50427 (2000-08-01), None
Homocamptothecis J. Med . Chem 1998 vol. 41 pp. 5410-5419.
Curran, D.P. and Liu, H., “New 4+1 Radical Annulations—A Formal Total Synthesis of (+/−)-Camptothecin,” J. Am. Chem Soc., 114, 5863-5864 (1992). Published Jul. 1, 1992.
Curran, D.P., “The Camptothecins—A reborn Family of Antitumor Agents”, J. Chin. Chem. Soc., 40, 1-6 (1993). Published Feb. 1993.
Curran, D.P. et al., “Recent Applications of Radical Reactions in Natural Product Synthesis,” Pure Appl. Chem., 65, 1153-1159 (1993). Published Jun. 1993.
Curran, D.P. et al., “Cascade Radical Reactions of Isonitriles: A Second-Generation Synthesis of (20S)-Camptothecin, Topotecan, Irinotecan, and Gl-147211C,” Angew. Chem. Int. Ed, 34, 2683-2684 (1995). Published Jan. 5, 1996.
Curran, D.P., Liu, H.; Josien, H; Ko, S.B., “Tandem Radical Reactions of Isonitriles with 2-pyrdonyl and other aryl radicals: Scope and Limitations, and a First Generation Sunthesis of (+/−)-Camptothecin,” Tetrahedron, 52, 11385-11404 (1996). Published Aug. 1996.
Josien, H. et al., “Synthesis of (S)-mappicine and Mappicine Ketone Via Radical Cascade Reaction of Isonitirles,” Tetrahedron, 53, 8881-8886 (1997). Published Jun. 30, 1997.
Josien, H. et al., “7-Silylcamptothecins (Silatecans): A New Family of Camptothecin Antitumor Agents,” Bioorg. Med. Chem. Lett. 7, 3189-3295 (1997).
Josien, H. et al., “A General Synthetic Approach to the (20S)-Camptothecin Family of Antitumor Agents by a regiocontrolled Cascade Radical Cyclization of Aryl Isonitriles,” Chem. Eur. J. 4, 67-83 (1998). Published Jan. 1998.
Zihou, M. et al., “Reduced Albumin Binding Promotes the Stability and Activity of Topotecan in Human Blood,” Biochemistry, 34, 13722-13727 (1995).
Burke, T.G. and Zihou, M., “The Structural Basis of Camptothecin Interaction with Human Serum Albumin: Impact on Drug Stability,” J. Med. Chemistry, 37, 40-46 (1994).
Zihou, M. and Burke, T.G., “Marked Interspecies Variations Concerning the Interactions of Camptothecin with Serum Albumins: A Frequency-Domain fluorescence Spectroscopic Study,” Biochemistry, 33, 12540-12545 (1994).
Zihou, M. and Burke, T.G., “Differential Interactions of Camptothecin Lactone and Carboxylate Forms with Human Blood Components,” Biochemistry, 33, 10325-10336 (1994).
Burke, T.G., and Zihou, M., “Ethyl Substitution at the 7 Position Extends the Half-Life of 10-Hydroxycamptothecin in the Presence of Human Serum Albumin,” J. Med. Chemistry, 37:17, 2580-2582 (1993).
Burke, T.G. et al., “Lipid Bilayer Partitioning and Stability of Camptothecin Drugs,” Biochemistry, 32:20, 5352-5364 (1993).
Zihou, M. and Burke, T.G., Preferential Binding of the Carboxylate Form of Camptothecin by Human Serum Albumin, Anal. Biochem., 212, 285-287 (1993).
Burke, T.G. and Tritton, T.R., “Structural Basis of Anthracycline Selectivity for Unilamellar Phosphatidylcholine Vesicles: An Equilibrium Binding Study,” Biochemistry, 24, 1768-1776 (1985).
Burke, T.G. and Tritton, T.R., “Location and Dynamics of Anthracycline Bound to Unilamellar Phosphatidylcholine Vesicles,” Biochemistry, 24, 5972-5980 (1985).
Burke, T.G. et al., “The Important Role of Albumin in Determing the Relative Human Blood Stabilities of the Camptothecin Anticancer Drugs,” J. Parm. Sciences, 84:4 (1995).
Burke Thomas G.
Curran Dennis P.
David Bom
Bartony & Hare, LLP
Desai Rita
University of Pittsburgh
LandOfFree
Camptothecin analogs and methods of preparation thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Camptothecin analogs and methods of preparation thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Camptothecin analogs and methods of preparation thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3731471